



Basel Breast Consortium

## TRICYCLE LUNCHTIME SEMINAR

Identification of mechanisms of resistance to Fulvestrant plus Ribociclib in ER+/HER2-advanced breast cancer

**Jorge Gomez, DBM, University Hospital Basel**

Immunecheckpoint Blockade in Breast Cancer – Current and Future standard of Care

**Anton Oseledchyk, University Hospital, Basel**

Imlunestrant, an oral selective estrogen receptor degrader, in estrogen receptor-positive advanced breast cancer

**Roohi Ismail-Khan, Eli Lilly, Switzerland**

**Tuesday, December 13, 2022, 12:30**

**Seminar room 2<sup>nd</sup> floor, ZLF - Hebelstrasse 20, Basel**

*Lunch buffet provided at 12:00 in front of the seminar room*

[www.baselbc.org](http://www.baselbc.org)